Welcome to our dedicated page for CapsoVision news (Ticker: CV), a resource for investors and traders seeking the latest updates and insights on CapsoVision stock.
CapsoVision, Inc. develops and markets capsule endoscopy technology for gastrointestinal imaging. The company’s flagship product, CapsoCam Plus®, is a wire-free panoramic capsule endoscope for small-bowel visualization with cloud-based or direct capsule video retrieval. News about CV commonly covers commercial adoption, quarterly financial results, account growth, product development and the company’s Nasdaq-listed public-company activity.
Recurring updates also include FDA submissions for AI-assisted capsule endoscopy tools, development work on CapsoCam Colon™, CMOS sensor development with Canon, private placement financing, investor conference participation and corporate governance or finance leadership changes.
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.
The company will host a conference call and live webcast at 4:30 PM ET on the same day. Investors can access the call by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with conference ID 1668374. A webcast will be available in the investor relations section of CapsoVision's website.
CapsoVision (NASDAQ: CV), a medical technology company specializing in capsule endoscopy solutions with advanced imaging and AI technologies, has successfully completed its Initial Public Offering (IPO). The company offered 5.5 million shares at $5.00 per share, raising gross proceeds of $27.5 million.
Trading commenced on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The underwriters, The Benchmark Company and Roth Capital Partners, have a 30-day option to purchase up to 825,000 additional shares at the IPO price, less underwriting discounts and commissions.
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has announced the pricing of its initial public offering (IPO). The company is offering 5,500,000 shares of common stock at $5.00 per share.
Trading is set to commence on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The offering, expected to close on July 3, 2025, aims to raise approximately $27.5 million in gross proceeds before deducting underwriting costs and other expenses. The underwriters have a 30-day option to purchase up to 825,000 additional shares at the IPO price.
The Benchmark Company and Roth Capital Partners are serving as joint book-running managers for the offering, which will be conducted through a prospectus as part of an SEC-approved registration statement.